Glenmark Pharma aims to turn cash positive by the end of the current fiscal. The drugmaker also expects respiratory and injectables to be the major contributors in FY25
Your email address will not be published. Required fields are marked *
Save my name, email, and website in this browser for the next time I comment.
Leave a Comment